Fundraising Fox
🦊/Companies
Sign in

Alpheus Medical

Chanhassen, US · Founded 2020 · Delaware corporation · 12 employees on LinkedIn · 5 known investors

Find your way into Alpheus Medical

Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites. The company's lead program is in a randomized Phase 2b trial for newly diagnosed glioblastoma.

BiotechHealthtechMedical Devices

Founders & leadership

JLJeremy Ling
Jeremy LinginChief Technology Officer
SW
Steve WeinerExecutive
VA
Vijay AgarwalinFounder, President, & CEOformer
WD
William DavisExecutive

Board

KV
Klaus VeitingerinExecutive ChairmanVenture Partner at OrbiMed
IEImran Eba
Imran Ebain𝕏Chief Financial OfficerPartner at Action Potential Venture Capital Ltd.
CWConrad Wang
Conrad WanginBoard Member2025–2026Partner at SLR Capital Partners
JMJuan-Pablo Mas
Juan-Pablo Masin𝕏Board DirectorPartner at Action Potential Venture Capital Ltd.
PTPeter Thompson
Peter ThompsoninBoard directorInvestor at OrbiMed
RS
Robert SteinBoard director

Investors · 5

OrbiMed✓ verifiedNew York · $1M – $75Mvia Klaus Veitinger · board
HealthQuest Capital✓ verifiedRedwood City
Samsara BioCapital✓ verifiedPalo Alto
SV Health InvestorsBoston · $1M – $20M
Action Potential Venture Capital Ltd.reportedScotts Valleyvia Juan-Pablo Mas · board

Reported raises · per SEC filings

Form D private placements

$82.7M disclosed across 7 rounds · 2017–2025

▶$60.5MraisedJul 2026 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Vijay AgarwalExecutive Officer, Director
  • Jeremy LingExecutive Officer
  • Imran EbaExecutive Officer
  • John JohnsonDirector
  • Robert SteinDirector
  • Juan-Pablo MasDirector
  • Peter ThompsonDirector
  • Klaus VeitingerDirector
  • Steve WeinerExecutive Officer
Offering amount
$67M
Amount sold
$60.5M
First sale
May 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14MraisedNov 2022 · 4 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter ThompsonDirector
  • Vijay AgarwalExecutive Officer, Director
  • Terrance KurtenbachExecutive Officer
  • Imran EbaDirector
  • Klaus VeitingerDirector
  • Aaron SandoskiDirector
Offering amount
$14M
Amount sold
$14M
First sale
Oct 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedDec 2020 · 23 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Vijay AgarwalExecutive Officer, Director
  • William DavisExecutive Officer
  • Imran EbaDirector
  • Peter ThompsonDirector
  • Aaron SandoskiDirector
  • Klaus VeitingerDirector
Offering amount
$16M
Amount sold
$6M
Sales commissions
$301.9K
Placement agents
B. Riley Securities, Inc.
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$519KraisedMay 2020 · 12 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Vijay AgarwalExecutive Officer, Director
  • William DavisExecutive Officer
Offering amount
$700K
Amount sold
$519K
First sale
Oct 2019
Incorporated
Corporation, North Carolina
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedOct 2018 · 22 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • William DavisExecutive Officer
  • Vijay AgarwalExecutive Officer, Director
Offering amount
$1.3M
Amount sold
$1.3M
First sale
Apr 2018
Incorporated
Corporation, North Carolina, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$150KraisedMar 2018 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • William DavisExecutive Officer, Director
  • Vijay AgarwalExecutive Officer, Director
Offering amount
$150K
Amount sold
$150K
First sale
Jan 2018
Incorporated
Corporation, North Carolina, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$225KraisedSep 2017 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Vijay AgarwalExecutive Officer, Director
  • Patrick GoraExecutive Officer
Offering amount
$300K
Amount sold
$225K
First sale
May 2017
Incorporated
Corporation, North Carolina, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Doximity6 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.

Companies competing with Alpheus Medical for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

HTML Sitemap | Alpheus Medicalalpheusmedical.com · Dec 2025Alpheus Medical Raises $52M to Advance Non-Invasive Glioblastoma Therapy into Phase 2B Trialjacobsmgt.com · May 2025Alpheus Medical Raises $52M in Series B Round : Alpheus Medicalalpheusmedical.com · May 2025Alpheus Medical raises $52M for ultrasound-activated tumor therapymassdevice.com · May 2025Alpheus Medical Raises $52M in Series B Round to Advance Groundbreaking Glioblastoma Therapy. | Alpheus Medicalalpheusmedical.com · May 2025Alpheus Medical Raises $52M in Series B Fundingfinsmes.com · May 2025

Frequently asked questions

What does Alpheus Medical do?
Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites. The company's lead program is in a randomized Phase 2b trial for newly diagnosed glioblastoma.
Who are Alpheus Medical's investors?
Alpheus Medical's investors include OrbiMed, HealthQuest Capital, Samsara BioCapital, SV Health Investors, Action Potential Venture Capital Ltd..
How much funding has Alpheus Medical raised?
Alpheus Medical has disclosed $82.7M raised across 7 rounds.
Where is Alpheus Medical headquartered?
Alpheus Medical is headquartered in Chanhassen, US.